CN Patent

CN101796055B — Vegf受体和hgf受体信号的抑制剂

Assigned to Mirati Therapeutics Inc · Expires 2013-09-04 · 13y expired

What this patent protects

本发明涉及抑制VEGF受体信号和HGF受体信号。本发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。本发明也提供了治疗细胞增殖疾病和病症的组合物和方法。

USPTO Abstract

本发明涉及抑制VEGF受体信号和HGF受体信号。本发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。本发明也提供了治疗细胞增殖疾病和病症的组合物和方法。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN101796055B
Jurisdiction: CN
Classification: —
Expires: 2013-09-04
Drug substance claim: No
Drug product claim: No
Assignee: Mirati Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.